India is on the verge of a major shift in the treatment of obesity and diabetes as the patent on semaglutide, the key ingredient in blockbuster weight-loss drugs, expires in the country.
The patent expiry opens the door for local pharmaceutical companies to manufacture cheaper generic versions of semaglutide, the compound behind widely used drugs such as Wegovy and Ozempic, both developed by Novo Nordisk. Industry analysts say this could significantly reduce treatment costs and expand access to millions of patients.
Investment bank Jefferies has described the development as a potential “magic-pill moment” for India, projecting that the domestic semaglutide market could grow to as much as $1bn if adoption increases and pricing becomes more competitive.
Experts predict a surge in competition, with as many as 50 branded generic versions expected to enter the market within months. This mirrors previous trends in India’s pharmaceutical sector, where the expiration of patents often leads to a flood of alternatives. For instance, when the diabetes drug sitagliptin lost patent protection in 2022, dozens of versions quickly became available.
India’s pharmaceutical industry, currently valued at about $60bn, is heavily driven by its generics segment and is projected to double by 2030. The country’s strength in producing affordable medicines could make semaglutide far more accessible, transforming what has largely been an expensive treatment for wealthy patients into a widely available option.
Originally developed to manage diabetes, semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which regulate blood sugar and appetite. These medications help patients feel full for longer periods, leading to significant weight loss, and have become increasingly popular worldwide.
Several major Indian drugmakers—including Cipla, Sun Pharma, Dr. Reddy’s Laboratories, Biocon, Zydus Lifesciences, and Mankind Pharma—are already preparing to launch their own versions.
Current monthly costs for treatment remain high, with Ozempic priced between 8,800 and 11,000 rupees, and Wegovy ranging from 10,000 to 16,000 rupees. However, analysts expect generic competition to push prices down to about 3,000–5,000 rupees, potentially tripling accessibility.
The anticipated price drop comes as India faces a growing public health challenge. The country has more than 77 million people living with type 2 diabetes and a rapidly increasing number of overweight adults, driven by sedentary lifestyles and high-carbohydrate diets.
Medical professionals say cheaper access to GLP-1 drugs could expand their use beyond diabetes treatment. Specialists in cardiology, orthopaedics, and respiratory medicine are already prescribing them to help patients lose weight before surgeries or manage related conditions such as sleep apnoea.
Despite the optimism, experts have raised concerns about safety and regulation. Side effects of semaglutide-based drugs can include nausea and digestive issues, while more serious complications, though rare, may occur. Doctors also warn against unrealistic expectations, noting that sustainable weight loss requires proper diet, exercise, and long-term management.
There are additional fears that wider availability could lead to misuse. Reports suggest some unqualified practitioners and online platforms are already promoting or prescribing these drugs without proper medical oversight, raising the risk of inappropriate dosing.
India’s role as the world’s largest supplier of generic medicines—accounting for about 20% of global supply—positions it to influence not just domestic access but also international markets. The country already exports pharmaceuticals to over 200 nations, including a significant share of generics used in the United States and the United Kingdom.
Industry leaders believe the export potential for low-cost weight-loss drugs could be substantial, especially as global obesity rates continue to rise. However, regulators have cautioned pharmaceutical companies against directly advertising such prescription drugs to consumers, emphasizing that they must be used under medical supervision.
As India prepares for a wave of cheaper semaglutide products, the coming months will likely test the country’s ability to balance affordability, quality control, and responsible use—while potentially reshaping the global fight against obesity.
Comments are closed.